News
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
2 Monster Stocks to Buy Without Any Hesitation
Investing in stocks is a great way for most people to grow their wealth over time. However, all stocks aren't created equal. Some are unlikely to deliver anything resembling solid returns over the
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
Why Merck Stock Rocketed Nearly 5% Skyward Today
Veteran healthcare company Merck (NYSE: MRK) was looking very healthy on the stock market Thursday. Its shares gained 4.6% in value across the day, following the publication of quarterly results
Merck (MRK) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q4 2023 Earnings CallFeb 01, 2024, 9:00 a.m. ET
Operator
Source Fool.com
EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I